文献速递产科母胎医学

糖基化纤连蛋白即时检验诊断东南亚资源有限地区子痫前期

Glycosylated fibronectin point-of-care test for diagnosis of pre-eclampsia in a low-resource setting: a prospective Southeast Asian population study.
PubMed 文献 · BJOG · 2020-06-16

本研究在印度798名≥20周孕妇中前瞻性评估糖基化纤连蛋白(GlyFn)即时检验诊断子痫前期(PE)的性能,并与PlGF、sFlt-1和PAPPA2比较,GlyFn的AUROC为0.99(0.98-0.99),表现最佳,提示其可作为资源有限地区PE诊断的辅助工具。

要点

  • GlyFn即时检验诊断PE的AUROC为0.99,优于PlGF、sFlt-1和PAPPA2。
  • GlyFn、sFlt-1、PAPPA2升高及PlGF降低均与临床定义PE显著相关(P<0.01)。
  • 48%的妊娠期高血压孕妇两种以上PE生物标志物阳性,其中70%早产。

核心结论

  • Lumella™ GlyFn即时检验已在低/中等收入国家验证用于PE诊断,可能有助于早期识别、合理分诊和改善结局。

研究设计与样本

  • 前瞻性病例对照研究,纳入798名≥20周孕妇,包括469名血压正常且尿蛋白/肌酐<0.3者、135例PE(高血压且尿蛋白/肌酐≥0.3)和194例妊娠期高血压(高血压且尿蛋白/肌酐<0.3)。

主要发现

  • GlyFn、sFlt-1和PAPPA2水平升高及PlGF水平降低与临床定义PE显著相关(P<0.01)。
  • GlyFn的AUROC为0.99(95%CI 0.98-0.99),PlGF为0.96(0.94-0.98),sFlt-1为0.86(0.83-0.89),PAPPA2为0.96(0.94-0.97)。
  • 妊娠期高血压孕妇中48%两种以上PE生物标志物阳性,其中70%早产。

关键数值与推荐

  • PE定义为高血压伴尿蛋白/肌酐比值≥0.3;妊娠期高血压定义为高血压伴尿蛋白/肌酐比值<0.3。
  • 研究采用逻辑回归模型和ROC曲线评估性能,并在特定阈值下报告分类性能及阳性/阴性预测值。

临床怎么用

  • GlyFn即时检验可作为资源有限地区PE诊断的辅助工具,用于早期识别和分诊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the performance of a glycosylated fibronectin (GlyFn) point-of-care (POC) test for pre-eclampsia (PE) in a large Southeast Asian cohort (India) in comparison to previously described biomarkers. DESIGN: A total of 798 pregnant women at ≥20 weeks of gestation were enrolled in a prospective case-control study. Study participants included 469 normotensive women with urinary mg protein/mmol creatinine ratio <0.3, 135 with PE (hypertension with urinary mg protein/mmol creatinine ratio ≥0.3) and 194 with gestational hypertension (hypertension with urinary mg protein/mmol creatinine ratio <0.3). METHODS: GlyFn levels were determined using a POC device and PIGF, sFlt-1 and PAPPA2 levels were determined by immunoassay. Performance was assessed using logistic regression modelling and receiver-operating characteristic (ROC) curves. Classification performance and positive and negative predictive values are reported at specific thresholds. RESULTS: Increased levels of GlyFn, soluble fms-like tyrosine kinase-1 (sFlt-1) and pregnancy-associated placental protein A2 (PAPPA2), and decreased levels of placental growth factor (PlGF) were significantly associated (P < 0.01) with clinically defined PE. Area under the ROC (AUROC) values with 95% confidence intervals were: GlyFn, 0.99 (0.98-0.99); PlGF, 0.96 (0.94-0.98); sFlt-1, 0.86 (0.83-0.89); and PAPPA2, 0.96 (0.94-0.97). Of subjects with GH, 48% were positive for more than two PE biomarkers, and 70% of these delivered preterm. CONCLUSIONS: The Lumella™ GlyFn POC test has been validated in a low/middle-income country setting for PE diagnosis and may be a useful adjunctive tool for early identification, appropriate triage, and improved outcomes. TWEETABLE ABSTRACT: The Lumella™ point-of-care test had excellent performance in diagnosing PE in a large Southeast Asian cohort.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Nagalla SR, Janaki V, Vijayalakshmi AR, et al. Glycosylated fibronectin point-of-care test for diagnosis of pre-eclampsia in a low-resource setting: a prospective Southeast Asian population study. BJOG. 2020. PMID: 32426899. doi:10.1111/1471-0528.16323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。